I disagree with your timelines and your premise. A deal can be made at any time, based on NON-PUBLIC information. We know that there is NON-PUBLIC information that CTIX has shown to people under a non-disclosure agreement.
Here are just a few things that could happen soon (or anyway much sooner than your timeline):
Some kind of interim results from Bril-OM, or a restructuring of the way the Prurisol data is analyzed. (Did they keep photos of all the patients, before, during and after? If so they ought to be able to evaluate the results in the same way that the currently-used drugs are being measured.) Likewise, drilling down on the Kevetrin results and giving us more data.
Commencement of another clinical trial for some sort of dermatological use.
Dana-Farber finally gets the Kevetrin article published.
Board of Director appointees, and/or more scientific staff added for clinical trials.
Change to OTCQB. Oh wait, that happened today.
And, of course, some kind of partnership that can happen at any time.
I am very encouraged by the steps that the company is taking. Dr. Bertolino is making sure that the clinical trials are being designed exactly correctly. I'd rather have him take time now, rather than have to repeat a trial later. And although I don't have any inside information any more than do all of the people who claim to know the inner workings of the company, I bet that part of the reason we're seeing such progress in development of the business end of the company (filings, OTC, etc) is because Leo doesn't have to do two people's jobs any more.
Here are just a few things that could happen soon (or anyway much sooner than your timeline):
Some kind of interim results from Bril-OM, or a restructuring of the way the Prurisol data is analyzed. (Did they keep photos of all the patients, before, during and after? If so they ought to be able to evaluate the results in the same way that the currently-used drugs are being measured.) Likewise, drilling down on the Kevetrin results and giving us more data.
Commencement of another clinical trial for some sort of dermatological use.
Dana-Farber finally gets the Kevetrin article published.
Board of Director appointees, and/or more scientific staff added for clinical trials.
Change to OTCQB. Oh wait, that happened today.
And, of course, some kind of partnership that can happen at any time.
I am very encouraged by the steps that the company is taking. Dr. Bertolino is making sure that the clinical trials are being designed exactly correctly. I'd rather have him take time now, rather than have to repeat a trial later. And although I don't have any inside information any more than do all of the people who claim to know the inner workings of the company, I bet that part of the reason we're seeing such progress in development of the business end of the company (filings, OTC, etc) is because Leo doesn't have to do two people's jobs any more.
1
